Hepatology Research

Article	Citations
Metabolic dysfunction‐associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients	122
Issue Information	107
Steroid administration for ischemic complications after radiofrequency ablation: A retrospective study	96
c‐Met inhibitor upregulates E‐cadherin, which is lost in portal vein tumor thrombus of hepatocellular carcinoma	78
	62
Issue Information	48
Issue Information	44
Is it necessary to revise the liver transplantation guidelines to meet the current situation?	42
Factors associated with portopulmonary hypertension	41
Diagnostic accuracy of hepatocellular carcinoma risk prediction models during antiviral therapy in chronic hepatitis B patients	40
Tumor steatosis and glutamine synthetase expression in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy	36
Questionnaire‐based approach to sleep‐wake disturbance in patients with chronic liver disease	33
Issue Information	32
Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B	32
Dysregulation of sphingolipid metabolic enzymes leads to high levels of sphingosine‐1‐phosphate and ceramide in human hepatocellular carcinoma	31
Low syntaxin 17 expression in donor liver is associated with poor graft prognosis in recipients of living donor liver transplantation	31
Toward the accumulation of evidence for a novel high‐sensitivity hepatitis B core‐related antigen assay in patients with hepatitis B virus infection	29
	26
Issue Information	26
Navitoclax improves acute‐on‐chronic liver failure by eliminating senescent cells in mice	24
Issue Information	24
Liver imaging reporting and data with perfluorobutane microbubbles—Is there hope?	24
Hypofractionated radiotherapy for hepatocellular carcinoma adjacent to the gastrointestinal tract	23
Issue Information	23
Development and validation of a prognostic model for 90‐day survival in patients with alcohol‐associated cirrhosis and acute decompensation	23

Issue Information	22
Clinical efficiency of inhibitory control test for the diagnosis of minimal hepatic encephalopathy: A systematic review with meta‐analysis	21
Prognosis of intrahepatic cholangiocarcinoma stratified by albumin–bilirubin grade	21
Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carc	20
Time‐resolved 3D cine phase‐contrast magnetic resonance imaging (4D‐flow MRI) can quantitatively assess portosystemic shunt severity and confirm normalization of portal flow after embolization of larg	19
Conditional recurrence analysis of intrahepatic cholangiocarcinoma: Changes in recurrence rate and survival after recurrence resection by disease‐free interval	19
Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs	17
Issue Information	17
Reversion of liver cirrhosis after endovascular treatment in Chinese patients with Budd–Chiari syndrome	17
Etiological changes of liver cirrhosis and hepatocellular carcinoma‐complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021	16
Issue Information	16
Integrated policy of medical expense subsidies and clinical registry for patients with liver cancer and decompensated cirrhosis in Japan	16
Optimal transplant strategy of pediatric liver transplantation for fibropolycystic liver disease: Multicenter retrospective study in Japan	15
Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study	15
Real‐world trends in acute viral hepatitis in Japan: A nationwide questionnaire‐based survey	15
Impact of antiviral therapy for disease progression and non‐invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis	14
Serum angiopoietin‐2 levels predict regression of Mac‐2 binding protein glycosylation isomer‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents	14
M‐PAST score is better than MAST score for the diagnosis of active fibrotic nonalcoholic steatohepatitis	14
Carbon‐ion radiotherapy versus radiofrequency ablation as initial treatment for early‐stage hepatocellular carcinoma	14
Clinical usefulness of noninvasive fibrosis indices for predicting hepatocellular carcinoma in treatment‐naïve patients with chronic hepatitis B following entecavir therapy	14
Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle‐aged and older US population	14
Artificial intelligence/neural network system that accurately diagnoses hepatocellular carcinoma in nonalcoholic steatohepatitis	13
Meta‐analysis of the diagnostic accuracy of serum type IV collagen 7S concentration for the staging of liver fibrosis in nonalcoholic fatty liver disease	13
Usefulness of the Fibrosis‐4 index and alanine aminotransferase at 1 year of nucleos(t)ide analog treatment for prediction of hepatocellular carcinoma in chronic hepatitis B patients	12
Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: how should we choose among these two latest and probably the last regimens?	12
The utility of biomarkers in prognosis assessment of patients with acute liver failure	12
Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib	12
Impact of bodyweight‐based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma	12
Perturbation of Wnt/β‐catenin signaling and sexual dimorphism in non‐alcoholic fatty liver disease	12
Issue Information	12
Postoperative direct‐acting antiviral treatment after liver resection in patients with hepatitis C virus‐related hepatocellular carcinoma	11
Automated image analysis of keratin 7 staining can predict disease outcome in primary sclerosing cholangitis	11
Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core‐related antigen assay	11
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study	11
Limited use of FIB‐4 index in patients under 65 years of age with type 2 diabetes mellitus	11
Circular ribonucleic acid nei‐like deoxyribonucleic acid glycosylase 3 governs the microribonucleic acid ‐3150b‐3p/laminin subunit gamma 1 network to partially promote the development of hepatocellula	11
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B	11
Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)	11
Real‐world efficacy of radiomics versus clinical predictors for microvascular invasion in patients with hepatocellular carcinoma: Large cohort study	11
Lean/normal‐weight metabolic dysfunction‐associated fatty liver disease is a risk factor for reflux esophagitis	10
Risk factors for relapse of autoimmune hepatitis in Japan: A nationwide survey	10
Measurement of multiple spleen lengths is not necessary for non‐invasive prediction of high‐risk esophagogastric varices	10
Non‐malignant portal vein thrombosis in a cohort of cirrhotic patients: Incidence and risk factors	10
The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A mu	10
Immunoglobulin G4 (IgG4)‐related autoimmune hepatitis and IgG4‐hepatopathy: A histopathological and clinical perspective	10
Impact of liver failure on the circulating extracellular vesicle miRNA repertoire	10
Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan	10
Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan	9
Role of PAR1 −506 deletion/insertion polymorphism in primary sclerosing cholangitis	9
Diagnostic criteria for acute‐on‐chronic liver failure and related disease conditions in Japan	9

aMAP score prediction of hepatocellular carcinoma occurrence and incidence‐free rate after a sustained virologic response in chronic hepatitis C	9
Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide seq	9
Refining the predictive utility of aspartate aminotransferase to platelet ratio index in nonalcoholic fatty liver disease patients with COVID‐19	9
Effects of sodium glucose cotransporter 2 inhibitors and pioglitazone on FIB‐4 index in metabolic‐associated fatty liver disease	9
Serum matrix metalloproteinase‐7 in biliary atresia: A Japanese multicenter study	9
Epidemiological assessment of hepatitis E virus infection among 1565 pregnant women in Siem Reap, Cambodia using an in‐house double antigen sandwich ELISA	9
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients	9
Distinct characteristics of MetALD (metabolic dysfunction‐associated steatotic liver disease with greater alcohol consumption) in the general population	9
Correlation between hepatic venous pressure gradient and portal pressure gradient in patients with autoimmune cirrhotic portal hypertension and collateral branches of the hepatic vein	9
Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta‐analysis of propensity score studies	9
Anticoagulation against portal vein thrombosis reduces mortality and liver cirrhosis‐related complications: A propensity score‐matched study	8
Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study	8
Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan	8
Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen	8
Serum levels of immunoglobulin M‐free inhibitors of macrophage/CD5L as a predictive and early diagnostic marker for nonalcoholic steatohepatitis‐associated hepatocellular carcinoma	8
Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma	8
Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”	8
Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease	8
Correction to Multicenter retrospective study of stereotactic body radiotherapy for patients with previously untreated initial small hepatocellular carcinoma	8
Importance of gamma‐glutamyl transferase elevation in patients with Fontan‐associated liver disease	8
Pancreatic congestion is associated with exocrine pancreatic function in liver cirrhosis	7
Improved survival outcome of curative liver resection for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma in the era of tyrosine kinase inhibitors	7
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy	7
Erratum	7
	7
Reply to Letter to the Editor: Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”	7
Brief intervention for chronic liver disease patients with alcohol use disorder in a hepatology outpatient unit: Effects and limitations	7
Liver‐to‐spleen ratio obtained from gadoxetate disodium‐enhanced magnetic resonance imaging predicts intrahepatic recurrence after curative resection of hepatocellular carcinoma	7
	7
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A categ	7
Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma	7
Angiopoietin‐like protein 4 deficiency augments liver fibrosis in liver diseases such as nonalcoholic steatohepatitis in mice through enhanced free cholesterol accumulation in hepatic stellate cells	6
Impact of post‐progression survival in second‐line treatment with molecular target agents for unresectable hepatocellular carcinoma	6
Issue Information	6
Pathological characteristics of liver sinusoidal thrombosis in COVID‐19 patients: A series of 43 cases	6
Prediction of hepatocellular carcinoma in patients with Fontan‐associated liver disease using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid magnetic resonance imaging	6
Proposal for new sleep disorder criteria in patients with chronic liver disease: Influence of liver‐related complications	6
	6
The metabolic evaluation of pemafibrate in nonalcoholic fatty liver disease‐related cardiovascular diseases	6
Abnormal fucosylation of alpha‐fetoprotein in patients with nonalcoholic steatohepatitis	6
Evaluating the liver function of patients with hepatocellular carcinoma	6
Impact of fibrosis on liver‐related event incidence in nonalcoholic fatty liver disease: A multicenter observational study	6
Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma	6
Clinical utility of postablation liver tumor biopsy and possibility of gene mutation analysis	6
Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors	6
Acknowledgment	6
Mitochondrial fission in hepatocytes as a potential therapeutic target for nonalcoholic steatohepatitis	6
Deciphering the dual nature of the Fibrosis‐4 index in predicting hepatocellular carcinoma risk among hepatitis B patients undergoing nucleos(t)ide analog therapy	6
Metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease: Which can better identify the populations with a high risk of cardiovascular disease?	6
Real‐world hospital mortality of liver cirrhosis inpatients in Japan: a large‐scale cohort study using a medical claims database	6
Effects of pemafibrate on primary biliary cholangitis with dyslipidemia	6
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity	6
Issue Information	6
Issue Information	6
Novel biomarkers of acute kidney injury in chronic liver disease: Where do we stand after a decade of research?	5
Safety and effectiveness of lusutrombopag in patients who have chronic liver disease with thrombocytopenia and undergoing invasive procedures: Real‐world post‐marketing surveillance in Japan	5
Impact of liver fibrosis on the relative abundance of a urease‐positive Streptococcus salivarius group from saliva in patients with chronic liver disease	5
Issue Information	5
A nation‐wide medical record database study: Value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan	5
Early‐phase prothrombin time‐international normalized ratio in acute liver injury indicates the timing of therapeutic intervention and predicts prognostic improvement	5
Issue Information	5
Clinical features of patients with chronic liver disease in Japan related to alcohol use: Nationwide examination using alcohol use disorders identification test	5
Algorithm of ascites management for liver cirrhosis in the tolvaptan era: Paradigm shift treatment improves the outcomes of cirrhotic patients?	5
Efficacy of rifaximin, a poorly absorbed rifamycin antimicrobial agent, for hepatic encephalopathy in Japanese patients	5
	5
Role of serum albumin in hepatic encephalopathy	5
An RNA‐degrading enzyme emerges as a biomarker in a study of human hepatitis virus B	5
Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study	5
Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma	5
Response to crizotinib in a patient with MET‐amplified hepatocellular carcinoma	5
Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma	5
Clinical significance of the latency period of abnormal ammonia metabolism in chronic liver disease: Proposal of a new concept	5
A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with he	5
Issue Information	5
Real‐world outcomes of molecular targeted agents for patients with hepatocellular carcinoma over 80 years old	5
Available weapons in our arsenal for de novo antibody‐mediated rejection following liver transplantation—Fighting an invisible foe	5
Transcriptomic and proteomic studies suggest the establishment of advanced zonation‐like profiles in human‐induced pluripotent stem cell‐derived liver sinusoidal endothelial cells and carboxypeptidase	5
Report of the 23rd nationwide follow‐up survey of primary liver cancer in Japan (2014–2015)	5
Causal association of nonalcoholic fatty liver disease with 22 extrahepatic cancers: A Mendelian randomization study	5
Successful second‐line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal–epithelial transition factor amplification	5

Combined effect of histological findings and diabetes mellitus on liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease	5
	5
Significance of the autoantibody assay in predicting the development of immune‐related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocel	5
	5
Mutations in the envelope protein associated with hepatitis B virus reactivation	5
Issue Information	5
	5